INKT · MiNK Therapeutics, Inc.
$11.27
+0.27 (+2.45%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the completion of anticipated funding is not entirely within the Company's control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 13, 2026
Market Cap
$57.51M
Shares
5.10M
MiNK Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for MiNK Therapeutics, Inc. (INKT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY26 · Q2
2026-08-13
MiNK Therapeutics, Inc. Q2 FY2026 Earnings Call
Confident tone
Agent 797 Phase 2 in ARDS / acute lung injury
Multi-drug resistant infections and biothreat
Named Patient paid access program in Brazil
Diluted EPS
$-0.62
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-15
MiNK Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone
ARDS / Severe Acute Lung Injury Program
INKT Cell Therapy Platform / Agent 797
Biomarkers & Mechanistic / Translational Findings
Diluted EPS
$-0.57
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q3
2025-12-08
MiNK Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
AGENT-797 Clinical Data in Solid Tumors
Safety Profile of iNKT Cell Therapy
Platform Biology and Mechanism
Diluted EPS
$-0.65
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
MiNK Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
iNKT Platform & Lead Candidate agenT-797
GvHD Prophylaxis Program
ARDS / Respiratory Distress
Diluted EPS
$-1.06
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
MiNK Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone
GvHD program and NIAID funding
Solid tumor clinical data (gastric and testicular)
Regulatory pathway and FDA engagement
Diluted EPS
$-0.70
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
MiNK Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
Clinical Pipeline / 797 in Oncology
Next-Generation Programs (PRAME-TCR, 215, Neoantigens)
Graft versus Host Disease (GvHD) Program & NIAID Funding
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
MiNK Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
Graft-versus-Host Disease program
iNKT cell platform and manufacturing efficiency
Agent 797 in gastric cancer (Phase 2)
Diluted EPS
$-0.46
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
MiNK Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
AgenT-797 in ARDS
Bispecific engagers and iNKT combination
MiNK-215 CAR-iNKT preclinical
Diluted EPS
$-0.73
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
MiNK Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
MiNK-215 CAR-iNKT (FAP) preclinical and discovery progress
agenT-797 Phase II gastric cancer trial
Combination strategy with checkpoint / T-cell activators
Diluted EPS
$-1.10
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
MiNK Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
iNKT cell platform and manufacturing capabilities
Phase 2 gastric cancer trial with agenT-797
Colorectal cancer MSS opportunity with bot/bal
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
MiNK Therapeutics, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-1.50
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
MiNK Therapeutics, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-1.70
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-21
MiNK Therapeutics, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
MiNK Therapeutics, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-1.90
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
MiNK Therapeutics, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-1.80
Audio
Transcript
Slides
8-K10-Q
Showing 1–15 of 15 earnings calls
Key facts
CIK
1840229
CUSIP
603693201
13F (30d)
28 filings
28 filers
Visit website
Investor relations